Autolus Therapeutics (NASDAQ:AUTL) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL - Free Report) in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

A number of other brokerages have also issued reports on AUTL. Wells Fargo & Company cut their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday, March 21st. Truist Financial decreased their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $9.32.

Autolus Therapeutics Trading Up 4.9 %

NASDAQ AUTL traded up $0.07 during trading hours on Thursday, reaching $1.41. The company had a trading volume of 920,763 shares, compared to its average volume of 1,450,529. The stock has a market capitalization of $373.86 million, a P/E ratio of -1.16 and a beta of 2.06. The stock has a 50-day moving average of $1.73 and a 200 day moving average of $2.60. Autolus Therapeutics has a 1-year low of $1.11 and a 1-year high of $5.25.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $2.98 million. As a group, sell-side analysts predict that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of large investors have recently modified their holdings of AUTL. Jane Street Group LLC purchased a new stake in Autolus Therapeutics during the fourth quarter worth approximately $26,000. Barclays PLC boosted its holdings in shares of Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after buying an additional 10,866 shares in the last quarter. Dumont & Blake Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics in the 4th quarter valued at $35,000. Arkadios Wealth Advisors purchased a new position in shares of Autolus Therapeutics during the fourth quarter worth about $47,000. Finally, Daiwa Securities Group Inc. increased its position in shares of Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.